Vimlarani Chopra

458 citations
8 papers · 378 indexed · h-index 7

Vimlarani Chopra

8 papers receiving 357 citations

Peers

Vimlarani Chopra
Comparison fields: 5 of 61
  • Molecular Biology 120
  • Oncology 95
  • Dermatology 78
  • Immunology 68
  • Cell Biology 60
Replace Edwige Roy with:
Edwige Roy Australia
John P. Seery United Kingdom
Atsumichi Urabe Japan
Khashayar Lessan United Kingdom
Ante Jelaska United States
P. De Waele Belgium
Hwan Chour Han Singapore
Karen Gambaro Canada
Hatixhe Latifi-Pupovci Kosovo
Céline Monvoisin France
Vimlarani Chopra relative to Edwige Roy Australia Edwige Roy's profile →
Citations per field
00.5×1.5×
Edwige Roy · 1×
Citations per year

Countries citing papers authored by Vimlarani Chopra

Since Specialization
Citations

This map shows the geographic impact of Vimlarani Chopra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vimlarani Chopra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vimlarani Chopra more than expected).

Fields of papers citing papers by Vimlarani Chopra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vimlarani Chopra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vimlarani Chopra. The network helps show where Vimlarani Chopra may publish in the future.

Co-authorship network of co-authors of Vimlarani Chopra

This figure shows the co-authorship network connecting the top 25 collaborators of Vimlarani Chopra. A scholar is included among the top collaborators of Vimlarani Chopra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vimlarani Chopra. Vimlarani Chopra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
#WorkIndexed citations
1 17
2
Oncogene expression and microvessel count in recurrent and nonrecurrent stage Ib squamous cell carcinoma of the cervix.
15
3 115
4 95
5 89
6 17
7 3
8 27

About Vimlarani Chopra

Vimlarani Chopra is a scholar working on Obstetrics and Gynecology, Cancer Research and Cell Biology, having authored 8 papers that have together received 378 indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (3 papers), Skin and Cellular Biology Research (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Dermatology (78 citations), Rehabilitation (50 citations) and Obstetrics and Gynecology (52 citations). Vimlarani Chopra has collaborated with scholars based in United States and Switzerland. Frequent co-authors include Tung Van Dinh, Edward V. Hannigan, Martin C. Robson, David N. Herndon, Robert L. McCauley, Stephen K. Tyring, Lorraine Johnson, Jo‐David Fine, Edward R. Smith and Hal K. Hawkins. Their work appears in journals such as Journal of Photochemistry and Photobiology B Biology, Journal of Clinical Immunology and Journal of Cancer Research and Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026